Cereno Scientific

We will initiate a sub-study of the ongoing CS1 Expanded Access Program (EAP) using non-invasive imaging technology from innovative medtech company Fluidda to further assess CS1’s disease-modifying potential to prevent or reverse pathological remodeling of blood vessels in the lung of patients. The local Institutional Review Board (IRB) has approved the sub-study design, enabling Cereno Scientific to immediately initiate the study.   The study is intended to support the translation of the well-documented reverse vascular remodeling effects of CS1 in preclinical models to clinical practice. The lack of non-invasive methods available to demonstrate this effect in patients present a challenge. The innovative imaging technology Functional Respiratory Imaging (FRI), developed by Fluidda, has been explored as a potential non-invasive tool to solve this challenge by providing detailed, patient-specific insights into pulmonary vascular changes. The study, also referred to as the “Fluidda study”, is designed to include three CT scans in certain patients enrolled in the EAP during a 12-month period. “By using the Fluidda technology, we will be able to obtain detailed images of the patient’s lungs and in so doing, detect changes in the pulmonary vasculature in patients treated with CS1. We believe that by monitoring the treatment response of CS1 with this technology, we will be able to capture signs of CS1’s reverse remodeling effect in PAH patients,” said Rahul Agrawal, CMO & Head of R&D of Cereno Scientific. "Our hope is to offer a pioneering approach to PAH therapy uniquely using HDAC inhibition as a mode of action in cardiovascular and pulmonary disease. CS1, part of our HDACi portfolio, targets the pathophysiology of disease progression in PAH with the potential to prevent or reverse vascular remodeling,” said Sten R. Sörensen, CEO of Cereno Scientific. "Following promising preclinical data and Phase IIa results, we aim to further understand CS1's disease-modifying potential with the Fluidda study.”   🔗Read more on the Cereno Scientific website: https://lnkd.in/dMmN_Yeb

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening condition caused by narrowing of small arteries in the lungs, leading to increased pressure and right heart failure. Key Facts About PAH: 🔹 No spontaneous improvement - PAH worsens over time. 🔹 Life expectancy is just 2.5 years without therapy, 7.5 years with current treatments. 🔹 The only cure is lung transplantation. 🔹 PAH is most common in women aged 30-60. 🔹 500-1000 new cases are diagnosed annually in the U.S. Cereno Scientific is working on a disease-modifying therapy to go beyond symptom management and enhance and extend the lives of people living with PAH. Learn more on our website: https://lnkd.in/excf4-u7 #PAH #PulmonaryHypertension #RareDisease #CardiovascularHealth

Cereno Scientific will be attending the 19th annual BIO-Europe Spring conference, taking place March 17–19, 2025, in Milan, Italy.   CEO Sten R. Sörensen shares: ‘‘BIO-Europe Spring® is a key annual event in Europe for pursuing partnering discussions. We look forward to building on a positive momentum to continuing discussions around our clinical-stage HDAC inhibitor portfolio, CS1 and CS014, both with disease-modifying potential…’’ Meet our leadership team in Milan to learn more about our innovative pipeline that offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full: Sten R. Sörensen, CEO Rahul Dr. Agrawal, CMO & Head of R&D 🔗 Schedule a meeting: https://lnkd.in/eRdjEqv #BIOEuropeSpring #RareDiseases #CardiovascularHealth #PulmonaryDiseases 

🎓 The definition of a rare disease varies by region. A disease is considered rare if it affects: 🔹 Fewer than 200,000 people in the U.S. 🔹 Less than 1 in 2,000 in the EU However, regardless of exactly how a rare disease is classified, the collective impact of rare diseases is enormous. 6,000+ rare diseases are estimated to affect over 300 million people worldwide. Current Treatment Challenges: 🔹 Many treatments focus on symptoms rather than addressing the underlying disease. 🔹 Safety and tolerability remain major concerns for many treatments. Cereno Scientific is pioneering safe and tolerable disease-modifying therapies that go beyond symptom management in order to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. 🔗 Learn more on our website: https://lnkd.in/excf4-u7 #RareDisease #CardiovascularHealth #PulmonaryHealth

Our HDAC inhibitor CS014 has successfully completed the first part of two in its Phase I trial in healthy volunteers without any safety concerns. CS014 is a novel histone deacetylase (HDAC) inhibitor with disease-modifying potential being developed for the rare disease idiopathic pulmonary fibrosis (IPF). The Phase I trial intends to evaluate the safety profile of CS014 in humans and is divided into two parts – a single ascending dose part (SAD) and a multiple ascending dose part (MAD). Part two of the trial (MAD) is currently ongoing according to plan and the Phase I trial is expected to be completed in mid-2025. “We are pleased with the progress of the CS014 Phase I trial and eagerly anticipate its completion in mid-2025. The successful completion of the single ascending dose (SAD) part provides a strong initial validation of HDACi CS014s favorable safety profile,” said Rahul Agrawal, CMO & Head of R&D. “We believe that our novel HDACi CS014 has the potential to become an important treatment meeting high unmet clinical needs in the rare disease IPF. There is a void in the market for safe and well-tolerated novel drugs with a profile addressing the underlying pathophysiology of the IPF disease and its progression. CS014 aims to be a safe, well-tolerated oral drug with disease-modifying capacity and, as such, targets a large market potential,” said Sten R. Sörensen, CEO. Read more on the Cereno Scientific website: https://lnkd.in/dU2cm923 #raredisease #pulmonarydisease

Cereno Scientific will present at the 2025 Nordic-American Healthcare Conference, the most comprehensive Nordic life science innovation gathering in the US. Sten R. Sörensen, CEO of Cereno Scientific, will present on March 26, 2025, to investors, corporate development executives and industry partners. This event is for registered attendees only, but the presentation will be available on Cereno Scientific’s website following the event. “Following on from the positive experience at J.P. Morgan Healthcare Week, we are pleased to continue dialogues around our clinical-stage HDAC inhibitor portfolio, CS1 and CS014, with disease-modifying potential. We are excited to discuss the significant progress that has been made these last twelve months with our lead program CS1 that reported positive top-line data from a Phase IIa trial in PAH and, our novel HDACi CS014 that is progressing towards completion of Phase I in mid-2025,” said Sten. Read more on the Cereno website: https://lnkd.in/dDCPBeqa #raredisease #cardiovasculardisease #pulmonarydisease

We’re back from the vibrant J.P. Morgan Healthcare Week in San Francisco, the major biotech/pharma event of the year gathering 20 thousand key decision makers in our industry, after a very productive and inspiring week. Sharing Cereno Scientific’s significant progress over the past year was a true highlight throughout the week. Our intense schedule of meetings with stakeholders ranged from potential pharma partners and investors as well as current and future advisors and clinical service providers - of which many we will continue discussions with as we move forward in 2025. Most importantly were the appreciative responses received when presenting our clinical stage HDAC inhibitor portfolio, CS1 and CS014, and discussing the connection between previously published preclinical data and our top-line data from the Phase IIa trial and the significant potential for disease-modifying capacity with our unique mode of action. The preclinical and clinical data supports the disease-modifying ability of our HDACi CS1 and demonstrates its potential to prevent and/or reverse pathological remodeling driving disease progression in PAH. Our key takeaway from these interactions is that there is a keen interest in the market for a pioneering treatment approach to rare and fatal cardiovascular and pulmonary diseases that our disease-modifying HDACi portfolio has the promise to fill. #JPMweek #JPM25 #BiotechShowcase

It was a pleasure to present at the #BiotechShowcase in San Francisco! Thank you to everyone who joined our session.   If you missed it, visit our website to learn more about how Cereno Scientific is well-positioned for strong growth in the cardiovascular and pulmonary rare disease market and on a mission to offer pioneering treatments to enhance and extend life. 👉 cerenoscientific.com   With an innovative pipeline of clinical and preclinical drug candidates, we are committed to addressing unmet patient needs while leveraging a strategic focus on rare diseases.   Our approach offers significant advantages, including shorter development timelines, lower capital requirements, and faster market entry potential, all while making a meaningful impact on underserved patient communities.   For more information, connect directly with our CEO, Sten R. Sörensen. #cardiovasculardisease #pulmonarydisease #raredisease

CEO, Sten R. Sörensen, will be presenting Cereno Scientific at the Biotech Showcase on Monday, January 13, at 2:00 PM in room Yosemite C (Ballroom Level) at the Hilton San Francisco Union Square Hotel.   Attend his presentation to learn more about Cereno’s Scientific’s innovative pipeline, which offers disease-modifying drug candidates that empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. #BiotechShowcase #JPMWeek

Press release: Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease pulmonary arterial hypertension (PAH). In total, the Expanded Access Program (EAP) now includes 10 patients with the possibility of more patients being included in the coming months. The additional data collected on the patients in the EAP will strengthen the long-term safety and efficacy documentation of CS1 and support regulatory interactions for future clinical trials. Read full release here: https://lnkd.in/dxfDvW7q